ReviewInternational journal of women's health2014
Clinical epidemiology of epithelial ovarian cancer in the UK.
Review in International journal of women's health, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 52 citations in OpenAlex.
- Article
- Time to adjuvant chemotherapy and overall survival in advanced-stage ovarian cancer patients in England: a population-based retrospective cohort study.ESMO real world data and digital oncology · 2025Article
- Mapping the Advanced-Stage Epithelial Ovarian Cancer Landscape Goes Beyond Words: Two Large Language Models, Eight Tasks, One Journey.Journal of clinical medicine · 2025Article
- Alteration of glucose metabolism and expression of glucose transporters in ovarian cancer.Exploration of targeted anti-tumor therapy · 2024Review
- Diagnosis, treatment and burden in advanced ovarian cancer: a UK real-world survey of healthcare professionals and patients.Future oncology (London, England) · 2024Article
- Ovarian Cancer in Iran: National Based Study.Iranian journal of public health · 2023Article
- Aging accelerates while multiparity delays tumorigenesis in mouse models of high-grade serous carcinoma.Gynecologic oncology · 2022Article
- Analysis of the association between KIN17 expression and the clinical features/prognosis of epithelial ovarian cancer, and the effects of KIN17 in SKOV3 cells.Oncology letters · 2021Article
- Enhancing delivery of small molecule and cell-based therapies for ovarian cancer using advanced delivery strategies.Advanced therapeutics · 2020Article
- Review
- Corilagin in Cancer: A Critical Evaluation of Anticancer Activities and Molecular Mechanisms.Molecules (Basel, Switzerland) · 2019Review
- Graphene Oxide-Based Targeting of Extracellular Cathepsin D and Cathepsin L As A Novel Anti-Metastatic Enzyme Cancer Therapy.Cancers · 2019Article
- Angiogenesis in Gynecological Cancers: Role of Neurotrophins.Frontiers in oncology · 2019Review
- Optical imaging of ovarian cancer using a matrix metalloproteinase-3-sensitive near-infrared fluorescent probe.PloS one · 2018Article
- Tumor-derived exosomes in ovarian cancer - liquid biopsies for early detection and real-time monitoring of cancer progression.Oncotarget · 2017Review
- Population pharmacokinetic and exposure simulation analysis for cediranib (AZD2171) in pooled Phase I/II studies in patients with cancer.British journal of clinical pharmacology · 2017Article
- Lack of HPV in Benign and Malignant Epithelial Ovarian Tumors in IranAsian Pacific journal of cancer prevention : APJCP · 2017Article
- Epidemiology of ovarian cancers in Zaria, Northern Nigeria: a 10-year study.International journal of women's health · 2017Article
- Ovarian cancer patients at high risk of BRCA mutation: the constitutional genetic characterization does not change prognosis.Familial cancer · 2016Article
- Is It Time to Centralize Ovarian Cancer Care in the United States?Annals of surgical oncology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epithelial ovarian cancer is the fifth commonest cancer among women and the leading cause of gynecological cancer death in the UK. Most women present with advanced disease, mainly because the nonspecific nature of the symptoms lead to diagnostic delays. Recent data have shown a fall in ovarian cancer mortality rates in the UK, but rates are still higher when compared to other European countries or the USA. In addition, surgeons in the UK achieve on average lower optimal surgical cytoreduction rates in patients with advanced ovarian cancer. Despite a wealth of information on epidemiological risk factors, the pathogenesis of epithelial ovarian cancer remains largely unknown. This review presents the most recent data on incidence, mortality, and survival for epithelial ovarian cancer in the UK. Time trends, trends by age, international comparisons, and regional variation in incidence, survival, and mortality are presented within the context of a major reorganization of cancer services that took place in the UK over 10 years ago. Centralization of cancer services has meant that women with ovarian cancer receive treatment in specialist Cancer Centers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.